Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Tattarang is the private investment group of Andrew and Nicola Forrest and one of Australia’s largest private investment companies. The firm invests across a broad portfolio of sectors including real assets, public and private markets, with interests spanning agri-food, energy, property, resources, lifestyle, and health technology. It is not a biotechnology, pharmaceutical, or healthcare operating company, but rather a diversified investment holding group. The company was formerly known as Minderoo Group and rebranded to Tattarang in 2020. For biotech analyst purposes, Tattarang is best understood as a non-health diversified investor that may hold healthcare-related investments rather than a therapeutic developer with an internal drug pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Tarrarang Group.